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Abstract 
Skeletal muscle channelopathies are a group of rare episodic genetic disorders comprised of 
the periodic paralyses and the non-dystrophic myotonias. They are a source of significant 
morbidity for patients, can limit their vocational opportunities, be socially embarrassing and 
in some cases are associated with sudden cardiac death. Diagnosis is often hampered by 
symptoms that may be difficult for patients to describe, a normal exam in the absence of 
symptoms and the need to interpret numerous tests that may be normal or abnormal. 
Symptoms are extremely responsive to holistic management and pharmacological treatment 
however, with great benefit to a patient’s quality of life. Here we review when to suspect a 
muscle channelopathy, how to investigate if you do, and the options for therapy once a 
diagnosis is made. 
 
Introduction 
Skeletal muscle channelopathies (SMCs) are a group of rare genetic neuromuscular disorders 
caused by dysfunction of sarcolemmal ion channels that are critical for muscle membrane 
excitability1. In simple terms they affect the ability of skeletal muscles to either contract, 
causing muscle weakness, or to relax, causing myotonia. This group of conditions is divided 
into the periodic paralyses and the non-dystrophic myotonias based on the predominant 
clinical symptom of either muscle weakness or myotonia. The hallmark of a skeletal muscle 
channelopathy is that symptoms occur in an episodic or paroxysmal fashion causing acute 
disability2. As a group they affect approximately 1 in 100 000 people in the U.K3. 
 
Myotonia (delayed muscle relaxation after contraction) is often described by patients as 
muscles “locking”, “sticking” or “cramping”. Episodic weakness can vary significantly from 
one limb “not working or feeling right” to quadriparesis. Symptoms commonly affect the leg 
muscles and in the case of myotonia may be precipitated by sudden or initial movement 
leading to falls and injury.  Symptoms are also exacerbated by prolonged rest, especially after 
preceding physical activity, and changes in environmental temperature4. Leg muscle 
myotonia can be particularly problematic on public transport which may stop abruptly 
causing falls or the patient may not be able to rise and exit quickly enough missing their 
destination. These difficulties can limit independence, social activity, choice of employment 
(based on ability to both travel to the location and to perform certain tasks) and are often 
socially embarrassing. The symptomatic relationship with activity often leads to sedentary 
behavior which in turn may be a risk factor for additional co-morbidities e.g. heart disease or 
stroke. Muscle channelopathies are also frequently painful with pain and impaired physical 
ability having a significant impact on quality of life5 6. 
 
The burden of morbidity in muscle channelopathies can usually be successfully ameliorated 
by readily available symptomatic treatments7 and the biggest barrier to improving a patient’s 
quality of life is more often a lack of diagnosis. Diagnosis is not always easy however, the 
conditions are rare and patients may be completely asymptomatic with a normal examination 
in the out-patient clinic. The diagnosis hinges on careful history taking arousing clinical 
suspicion supported by an accumulation of examination findings (or lack of abnormality) and 
investigative clues. There is no single test that will provide an answer in isolation.  
Here we review when to suspect a skeletal muscle channelopathy, how to investigate for one 
when you do and how to manage symptoms and disability after diagnosis. 
 
Clinical history 
Skeletal muscle channelopathies include the periodic paralyses and the non-dystrophic 
myotonias. The periodic paralyses are hypokalaemic periodic paralysis (hypoPP), 
hyperkalaemic periodic paralysis (hyperPP) and Andersen-Tawil Syndrome (ATS). The non-
dystrophic myotonias are paramyotonia congenita (PMC), sodium channel myotonia and 
myotonia congenita (MC) (see Fig 1 for causative genes and the resultant dysfunctional ion 
channels). These are genetic disorders and in the majority of cases symptoms can be traced 
back to the first or second decade highlighting the importance of taking an early life history. 
In some cases symptom onset can be delayed into the 30s or 40s and/or may only appear 
during certain life events e.g. pregnancy. 
The periodic paralyses 
HypoPP and hyperPP are named in relation to episodes of muscle weakness occurring in the 
presence of either high or low serum potassium levels8. They can be further distinguished by 
the typical pattern and duration of attacks and symptomatic triggers that drive serum 
potassium up (foods high in potassium) or down (carbohydrate meals) – see Fig 2. Myotonia 
can also be present in hyperPP but episodic weakness is usually the presenting complaint. 
When taking a history of someone with possible periodic paralysis several caveats are 
important to bear in mind. Despite being called periodic paralysis not all episodes of 
weakness are this dramatic. The most profound episodes do include quadriparesis and these 
cases are most likely to present to the emergency department with deranged (often low) 
potassium. Many patients however will describe more modest weakness e.g. they can stand 
but only furniture walk, or they are able to walk on the flat but feel weak and can’t run or 
climb stairs. Weakness will often present with a period of rest following physical activity. A 
common early event or recollection of symptoms is having played with friends during school 
lunch break, returning to sit at a desk for lessons and then being unable to stand or walk. 
Sometimes weakness may seem task specific or only affect one limb e.g. the dominant hand 
is weak after a prolonged period of writing. In these cases there is usually a history of more 
generalised weakness but these may be the only symptoms initially volunteered as they are 
the most troubling. 
HypoPP characteristically presents in the early teens with episodes of weakness experienced 
on waking and lasting several hours. If this results in being unable to attend school in the 
morning but appearing “normal” by the afternoon it may be mis-interpreted as school 
avoidance9. Similar scenarios can lead to disciplinary procedures for working adults.  
The recurring episodes of weakness in periodic paralysis although similar are not usually 
stereotyped. Stereotyped episodes are more indicative of a paroxysmal movement disorder or 
episodic ataxia and the term “weakness” may be used erroneously by a patient struggling to 
quantify a difficult to describe symptom e.g. dyskinesia.   
Andersen-Tawil Syndrome 
ATS is the only skeletal muscle channelopathy to affect any system other than skeletal 
muscle – namely cardiac muscle and bony development. The classical syndrome is described 
as a triad of periodic paralysis (usually mirroring the hypoPP variety), cardiac conduction 
defects and dysmorphic features10. In many cases however, the dysmorphic features can be 
subtle and overlooked and the skeletal or cardiac muscle symptoms may dominate the clinical 
picture obscuring the true breadth of systematic involvement. Patients predominantly affected 
by periodic paralysis may be mis-diagnosed as hypoPP. This has important implications as a 
lack of awareness of cardiac risk and subsequent monitoring can be detrimental. Sudden 
cardiac death is described in ATS but generally considered a rare event. Emerging evidence 
indicates however that cardiac arrhythmias requiring medical intervention are relatively 
common with an ICD required in 20% of patients in one series11, and may occur without 
prominent cardiac symptoms. We recommend yearly cardiac review by an experienced 
cardiologist with ECG and prolonged Holter monitor in all patients with ATS (regardless of 
symptoms). 
The non-dystrophic myotonias 
Myotonia is usually the presenting complaint in both myotonia congenita and paramyotonia 
congenita. It can be difficult for patients to describe (especially before a diagnosis is made) 
and terms such as muscles cramping, being stiff, stuck, aching, or “not working” may be 
used. Myotonia can affect any skeletal muscle so although typical patterns of involvement 
occur (legs more than hand and face in MC, hands and face more than legs in PMC), 
symptoms affecting the trunk, back (back pain) and chest muscles (unable to catch 
breath/take a deep breath) can all be problematic. Myotonia affecting the face can include the 
jaw and tongue making chewing or swallowing difficult especially if a cold item or drink is 
consumed. Cardiac and smooth muscle (bowel or bladder) are not affected in the non-
dystrophic myotonias. 
Other characteristic pointers towards either a diagnosis of MC or PMC include the presence 
of the warm up phenomena in MC (myotonia improving with repetitive activity) or 
paradoxical myotonia in PMC (worsens with repetition) as well as different forms of episodic 
weakness (see Table 1). Sodium channel myotonia can have overlapping features of both MC 
and PMC but refers essentially to a pure myotonic disorder without any episodic weakness 
due to mutations in the SCN4A (sodium channel) gene. 
Myotonia itself is a symptom and/or sign, not a diagnosis. Myotonia can be seen or detected 
during EMG in other conditions including myotonic dystrophy type 1 and 2, Pompes 
disease12 and other myopathies13 (where it may be detected on EMG only without overt 
clinical signs) or be drug induced14. Of all possible differentials for a patient with myotonia, 
myotonic dystrophy type 1 is by far the most common and should always be considered 
especially in younger patients who may not yet manifest the multi-system involvement of this 
disorder. In addition, although less common than DM1, the systemic features of DM2 are 
often more mild (even at older ages) causing confusion with non-dystrophic myotonia.  
Pain and fatigue 
Episodic weakness or myotonia are the dominant clinical symptoms in the SMCs but pain 
(myalgia) and fatigue are often prominent and in some cases may be the symptom causing the 
most concern to the patient5 6 15. It is important to enquire about these and to attempt to treat 
them as well as addressing weakness and myotonia. 
Examination findings 
Typical examination findings in the periodic paralyses are normal although a proportion of 
patients do develop a proximal myopathy. If examined during an episode of weakness, in 
addition to reduced power, reflexes are reduced or absent. Myotonia may be detectable in 
someone with hyperPP. Patients with Andersen-Tawil syndrome can have dysmorphic 
features including short stature, low set ears, micrognathia, clinodactyly, dental 
abnormalities16 (these may have been corrected in childhood so important to enquire in the 
history about dental work, especially extraction for overcrowding). 
Those with myotonia often have generalised muscle hypertrophy, or well defined muscles9. 
They are also often young adults when they present and it is easy to assume they look this 
way because they are young and fit. Muscle hypertrophy must always be considered in 
context and a specific enquiry made as to how active or how many times a week your patient 
actually attends the gym. 
Patients with a myotonic disorder will (nearly always) have evidence of myotonia on 
examination but it can be easily overlooked in a general neurological exam. Patients with MC 
are best diagnosed from the waiting room. It is likely they will have sat for some time waiting 
to be called. When they first rise leg muscle myotonia will cause them to be slow and to have 
a stiff gait. By the time they have walked with you to the clinic room this is often normal. 
Examination for eyelid closure or hand grip myotonia should be repeated. If the patient has 
PMC the first movement may appear unrestricted and it is only with repetition that myotonia 
becomes evident (paradoxical myotonia). Conversely for MC myotonia may be immediately 
evident with the first test but improves or disappears with repetition i.e. the warm up 
phenomenon may be demonstrated. We usually ask the patient to grip their hands tightly or 
close their eyes “as if they have soap in them” for 5 secs, then to open the hand/eyes as fast as 
possible. This should be repeated 3 to 5 times. Other findings can include contractures e.g. at 
the elbow and scoliosis although this is most commonly seen in children and young adults. 
Investigations 
Investigations performed when considering the possibility of a muscle channelopathy need to 
be interpreted in light of the overall presentation as a negative test in isolation does not 
exclude a channelopathy.  
Bloods tests/CK 
The role of blood tests in investigating a SMC is largely in excluding other differential 
diagnoses. A standard “battery” includes renal function (is there any evidence of renal disease 
causing deranged potassium levels), thyroid function tests (does your patient have thyrotoxic 
periodic paralysis), white cell enzymes (Pompe’s disease) and creatine kinase (CK). Creatine 
kinase typically ranges from within normal limits to up to 1000IU/L6. It is a non-specific test 
but an abnormal result always helps to lend support to the suspicion of a neuromuscular 
disorder. However, a normal result does not exclude a SMC. Values above 1000IU/L can 
occur and are consistent with a SMC diagnosis but they are less common17 and with values 
this high it is always worth considering the whole presentation and asking if this could reflect 
an alternative neuromuscular diagnosis (see table 2). Rare cases of CKs above 10 000IU/L 
and presentation with rhabdomyolysis have been reported in the SMCs18. 
Ictal potassium levels are helpful but not absolute in a patient with possible periodic 
paralysis. If weakness is severe enough to cause quadriparesis potassium levels usually lie 
outside a normal range. The key element associated with weakness however is a rise or fall in 
potassium levels and the absolute value is not always outside normal limits. This can be 
especially true if an attack is beginning to subside, or has subsided by the time any blood tests 
are taken.  
Neurophysiology 
Standard EMG and NCS assessments are usually normal in the periodic paralyses (with the 
exception of the presence of myotonia in some cases of hyperPP). If considering a diagnosis 
of periodic paralysis the most informative test is a long exercise test (LET)19. This involves 
stimulating the ulnar nerve and recording a series of CMAPS from abductor digiti minimi 
before and after “exercise” of the muscle (abduction against resistance over a 5 minute 
period). The post-exercise CMPAPs are recorded for a 50minute period looking for a greater 
than or equal to 40% decline in CMAP amplitude compared to the post-exercise peak. If 
positive this indicates periodic paralysis but not the sub-type. In a significant minority of 
cases, especially in those with ATS as well as patients who have rare attacks of weakness, the 
LET can also be within normal limits20. So a positive test is helpful but a negative test does 
not exclude a diagnosis of periodic paralysis. 
EMG will determine the presence of myotonia. This is non-specific and once myotonia is 
identified the differential diagnoses (see Table 2) all need to be considered. Electrical 
myotonia without clinical myotonia is more commonly seen in the presence of a myopathic 
disorder but usually there are other indicators of this e.g. myopathic EMG, fixed weakness on 
exam and persistent functional disability. A repeat short exercise test can illustrate certain 
patterns of response that help to indicate the different sub-types of non-dystrophic myotonia21 
but there is overlap with the patterns seen in myotonic dystrophy and it is not specific. With 
the advent of next generation sequencing allowing genes to be sequenced in parallel, rather 
than having to choose a “first choice” this test has less practical value in everyday clinical 
practice. 
Genetic testing 
Next generation sequencing (NGS) means that in the UK parallel testing of all genes 
indicated in SMC is now available. This has particular benefit for ATS which may present as 
a hypoPP picture clinically but an accurate diagnosis will be detected by NGS which includes 
analysis of all three periodic paralysis genes, SCN4A, CACNA1S and KCNJ2. Due to the 
cardiac risks of ATS we recommend all relatives of a proband are offered genetic testing 
regardless of symptoms. 
For a possible myotonic disorder, CLCN1 and SCN4A are also analysed in parallel. DM1 and 
DM2 genetic testing needs to be requested separately and should not be forgotten even if the 
patient appears to “only” have a myotonic disorder. 
In terms of inheritance pattern all of the SMCs are autosomal dominant or de novo with the 
exception of myotonia congenita which can be dominant or recessive. Recessive CLCN1 
variants can co-segregate with an SCN4A variant or an expansion in the DMPK and CNBP 
genes associated with DM1 and DM2. This can cause diagnostic confusion e.g. if a proband 
is diagnosed clinically with MC and genetic analysis reveals one variant in a family with 
dominant inheritance of a myotonic disorder, it may be assumed that this reflects a positive 
diagnosis when in fact the proband may be a carrier for a recessive CLCN1 variant and have 
myotonic dystrophy. This has clinical implications as monitoring for cardiac and other 
systemic complications will be omitted if diagnosed with myotonia congenita. 
The characteristic phenotypes of SMC have been described for over 100 years and the genetic 
basis of these disorders known since the early 1990s. A significant minority of patients do 
present with a channelopathy like clinical presentation but have a negative genetic result for 
these established disease causing genes. 
In the last few years a number of alternative genetic causes of episodic neuromuscular 
weakness with expanding phenotypes have been identified22 23. Other neuromuscular 
diagnoses can also have episodic or fluctuant presentations e.g. metabolic disorders (see 
Table 2) and do need to be considered if genetic testing for a SMC is negative. In addition 
other paroxysmal disorders, especially GLUT 1 deficiency and Paroxysmal Kinesigenic 
Dyskinesia (PKD), can erroneously be referred to a neuromuscular clinic24. 
Other investigations – MRI and muscle biopsy  
MRI scanning of the muscles, usually lower limb muscles in SMC can demonstrate fatty 
infiltration of the muscles in keeping with the clinical development of fixed myopathy25 or T1 
STIR hyperintensity. In the case of periodic paralysis the STIR hyperintensity is thought to 
be reflective of disease activity i.e. ongoing recurrent episodes of weakness. This can be 
useful in terms of guiding symptomatic treatment and response. Early pattern recognition 
including a gastrocnemius “central stripe” in myotonia congenita26 are proposed as diagnostic 
pointers (Fig 3) but a definitive MRI pattern of muscle involvement is not yet established for 
SMCs. 
A muscle biopsy is not necessary or generally informative for the diagnosis of typical SMC. 
Those that have been performed historically have illustrated non-specific myopathic findings 
including the presence of a vacuolar myopathy in periodic paralysis27. Exceptions to this 
include the newer and atypical phenotypes of channelopathy e.g. RYR1 related periodic 
paralysis where a muscle biopsy can be supportive of the diagnosis22. 
Management  
SMCs are genetic disorders which currently are not curable but there are numerous 
symptomatic treatments and management approaches that can have a significant impact on 
morbidity. 
Lifestyle and activity 
There are clear symptomatic triggers for many patients with SMCs e.g. foods high in 
carbohydrate or potassium. Keeping a food diary can be a useful way to identify these and 
help to avoid them or make alternative food choices.  
The relationship between symptoms and exercise means that many people with SMCs 
describe exercise and activity avoidance, low levels of physical activity, and difficulties 
maintaining an active lifestyle. However, people who have been able to develop ways of 
keeping active do describe this as beneficial.  
The benefits of keeping active, in terms of extending health-span, are well established for the 
general population and for people with long term conditions. Correlations between extended 
periods of inactivity (sedentary behaviour), health outcomes including obesity, cardiovascular 
and metabolic diseases, and increased risk of mortality have also been reported for the 
general population28 29.  
Little is published about activity in SMCs specifically, although our personal experience 
suggests a trend for high levels of sedentary behaviour in this population, indicating that 
interventions addressing this may help improve health outcomes.   
Advice on extended periods of warm up and cool down, and stretches before and after 
exercise, can support an individual to transition in and out of, and prepare for exercise, 
without precipitating symptoms and/or in some cases associated muscle pain. Low intensity 
and low resistance exercises, focusing on gradually increasing repetitions and resistance as 
muscles adjust can also help to avoid an increase in myotonia, or precipitation of weakness. 
The use of activity monitors or apps can be helpful tools to measure activity, and to establish 
a baseline from which individuals can set goals to gradually increase activity and/or interrupt 
extended periods of sedentary behaviour. Walking and moving around is often more 
accessible than formally working out at the gym. 
Fatigue may also benefit from these approaches or may require additional referral to a formal 
fatigue management programme. 
Pharmacological therapies 
Some patients will choose to manage symptoms by adjustment of triggers as much as 
possible7. When medication is indicated there are numerous choices. In the periodic paralyses 
prophylactic treatment is aimed at controlling potassium levels with either daily potassium 
sparing (aldosterone antagonists e.g. spironolactone, or amiloride) or potassium wasting 
(thiazides) diuretics. For those with hypoPP potassium supplements taken at the onset of an 
attack can also help to abort or minimise symptoms7. Other options shown to be effective in 
both forms of periodic paralysis include carbonic anhydrase inhibitors acetazolamide, or 
dichlorphenamide (not currently available in England). Long-term acetazolamide requires a 
yearly renal ultrasound scan to monitor for the development of renal calculi. Treatment of 
non-dystrophic myotonia of any sub-type is with sodium channel blockers. Mexiletine is 
most widely used and has the greatest available evidence of efficacy and safety30-32 but 
lamotrigine is increasingly popular following a recent clinical trial33. Other options with more 
limited or anecdotal data include ranolazine, carbamazepine, flecainide, propafenone and 
phenytoin. All options are primarily aimed at treating either episodic weakness or myotonia. 
There are no studies to indicate the best treatment of pain or myalgia in SMCs. Our personal 
experience is that acetazolamide, often combined with an anti-myotonic agent e.g. mexiletine 
can be beneficial in the NDMs but that analgesics, including neuropathic agents, often have 
limited benefit. 
It is unknown if aggressive control of episodic symptoms has any influence on the longer-
term development of a proximal myopathy that can occur in NDMs but there is some limited 
evidence that it may. 
Cardiac management 
Yearly follow up with a cardiologist is recommended for all patients with ATS. Extended 
ECG recording e.g. 24 or 72 hour Holter monitors may have benefit in detecting arrhythmias 
requiring treatment even when symptoms are not reported. There is no RCT evidence for the 
most effective anti-arrhythmic regime but beta-blockers or flecainide are commonly used. 
The requirement for interventional devices such as an ICD appears to be more common than 
previously appreciated emphasising the importance of expert cardiac involvement11. 
Emergency treatment of periodic paralysis  
Due to the extended nature of attacks those with hypokalaemic periodic paralysis tend to be 
the patients with SMCs who most commonly present to the emergency department. All 
patients presenting with a first episode of hypokalaemic periodic paralysis should be 
investigated for secondary causes of hypokalaemia especially thyrotoxicosis (Fig 2). In the 
event of low potassium, ECG monitoring is required. If ECG changes occur this is an 
indication to use IV rather than oral potassium replacement. ECG and potassium monitoring 
must continue during replacement and for several hours post-correction to normal range. This 
is because during an attack, potassium is held intracellulary but total body potassium is not 
actually low. As the attack subsides, potassium returns to the serum. If this is combined with 
exogenous replacement it can result in a rebound hyperkalaemia and iatrogenic death34. 
Pregnancy and labour 
The majority of pregnant women do report symptoms of SMCs are exacerbated when they 
are pregnant35 36. This may be due to both hormonal changes and the current recommendation 
that medication is discontinued prior to and during pregnancy due to evidence of 
teratogenicity or a lack of safety data. There are some reports of mexiletine having been used 
without major adverse event during pregnancy37 38 and more recently the evidence of efficacy 
for lamotrigine in myotonic disorders33 offers a potential new option for pregnant women. 
Worsening symptoms can be particularly detrimental if they provoke increased falls or they 
may necessitate taking maternity leave early which has a knock on effect of limiting time 
available to spend with baby post-partum. 
Many women with SMCs have spontaneous unassisted vaginal deliveries, and this option 
should not be routinely denied when birth planning. We usually recommend labour is 
considered relatively high risk however in the sense that labour takes place in a facility where 
senior paediatric, obstetric and anaesthetic staff and facilities are available if required. 
Symptoms of weakness or myotonia may prolong a labour and delivery with all the inherent 
complications of this, but in addition, a subgroup of infants can have life-threatening 
respiratory complications if they have inherited the disorder39 (predominantly those at risk of 
inheriting an SCN4A gene mutation). 
Anaesthetic considerations 
For any patient requiring an anaesthetic (including during labour) it is essential the 
anaesthetist be informed of the diagnosis of SMC beforehand, where feasible. Local or 
regional anaesthetics are preferred to a general anaesthetic if possible. If general anaesthesia 
is used propofol and non-depolarising anaesthetic agents appear to be effective and safe40. 
Depolarising anaesthetics or suxamethonium can precipitate a myotonic crisis with profound 
muscle rigidity which can mimic a malignant hyperthermia type reaction. If the rigidity 
includes the jaw muscles intubation may be impossible41. Suxamethonium can also induce 
hyperkalaemia and ventricular arrhythmia which can be fatal42. Emergency treatment for a 
myotonic crisis is with intravenous sodium channel blockers e.g. lidocaine40. 
It should be noted that other peri-operative factors can also exacerbate symptoms of a SMC 
e.g. prolonged immobility, or a cold operating theatre/recovery room. 
In summary skeletal muscle channelopathies are rare. They can evade diagnosis because they 
are sometimes hard for a patient to describe, often have no positive examination findings and 
investigations may be normal or negative unless conducted during symptoms. Yet they are 
extremely treatable and the benefits of appropriate diagnosis and management while 
rewarding for clinicians, are profound for patients. 
Key Messages 
When assessing a myotonic disorder without obvious systemic involvement don’t forget 
myotonic dystrophy 
Symptoms of a muscle channelopathy are more than weakness and myotonia, pain and 
fatigue can be prominent 
Andersen-Tawil Syndrome requires cardiac monitoring regardless of symptoms 
Episodic movement disorders can be confused with a muscle channelopathy and vice versa 
Skeletal muscle channelopathies are treatable disorders  
 
Case Example: A weak patient in A and E with a low potassium – is it periodic 
paralysis? 
History  
Hypokalaemia from any systemic, drug induced or genetic cause can induce muscle 
weakness. Ask the patient if they have diarrhoea and vomiting, tachycardia and palpitations 
(thyrotoxicosis), is there a known history of renal disease, take a drug history and family 
history (is there a known family history of PP or other relatives with the same symptoms)? 
Has this happened before or have they had milder symptoms of weakness that resolved 
spontaneously without the need to attend A and E? The age of the patient can be indicative. 
Drug history may be more pertinent in older patients. Genetic disorders are more likely to 
present for the first time in younger patients, the typical age of onset of hypoPP being in the 
teens. These are of course pointers only and age is not an absolute criteria for genetic causes 
of periodic paralysis. 
Examination 
Weakness typically affects the limbs and trunk with reduced or absent reflexes. Muscles of 
the neck and face are less commonly affected but can be. This may cause speech to sound 
slurred if the lower face and tongue are weak or for there to be eye closure weakness. 
Extraocular muscles are not usually weak and an inability to speak or open eyes at all is not 
typical and more indicative of functional weakness. In young children with hypoPP 
respiratory muscle weakness can cause respiratory distress and hypoxia. This is much less 
common in teenagers and adults but can occur in severe episodes with quadraparesis. Does 
the patient look dysmorphic? Do they have short stature? Short stature and dysmorphic 
features vary widely in ATS but among the most common are micrognathia (small chin), 
clinodactyly (curved digit, usually the little fingers) and low set ears. Are there any other 
systemic abnormalities? Hypertension may accompany secondary causes of hypokalaemia. 
Tachycardia may indicate thyrotoxicosis but can occur with hypokalaemia itself or may just 
indicate the patient is anxious about being unable to walk. 
Initial Investigations and Management 
Hypokalaemia with normal acid-base balance is expected in genetic forms of hypoPP, acid-
base disturbance should prompt more extensive renal, and endocrine investigations for e.g. 
renal tubular acidosis, Gitelman’s syndrome, hyperaldosteronism. Given that the 
hypokalaemic weakness may be the only indicator of thyroid disease we recommend 
routinely testing all first presentations. Creatine kinase can be normal or raised and is non-
specific to diagnosis but a positive test can be useful in a general setting to triaging an 
onward referral after the acute episode. 
Monitor the ECG and serum potassium levels. There is no absolute value for when to choose 
oral versus IV replacement but a potassium <2.5mmol/l, severe muscle paralysis especially if 
breathing is impaired or ECG changes of hypokalaemia (flat T waves, u waves, ST segment 
depression) are indicators for IV potassium. A typical dose of 40mmol/l KCl in 1L of 0.9% 
NaCl given at a rate of 10mmol/hour is usually sufficient but local guidelines should be 
consulted.  If potassium replacement is given it is mandatory to monitor the ECG throughout 
and for several hours after normokalaemia as there is a risk of rebound hyperkalamia.

















































































































Can occur Can occur No Yes can be 
generalised 
*before the genetic basis of channelopathies was known many clinical phenotypes were described including potassium aggravated myotonia, acetazolamide 
responsive myotonia but these were subsequently all shown to be due to mutations in the SCN4A gene and are now collectively called sodium channel 
myotonia. 
Table 1: Clinical features of the non-dsytrophic myotonias 
 
Diagnosis Comment 
Myopathies – Pompe’s disease, 
myofibrillar myopathy 
May have electrical myotonia on EMG. 
Myopathies – Metabolic, McArdles 
disease, RYR1 related 
Episodic symptoms, often related to physical exertion, can be confused with periodic paralysis. 
A specific RYR1/PP overlap syndrome has recently been identified. 
Becker muscular dystrophy Large calves occasionally confused with calf hypertrophy seen in myotonia congenita. 
Secondary causes of hypokalaemia e.g. 
renal disease, drug induced 
Profound hypokalaemia can induce muscle weakness in any individual in the absence of a genetic 
predisposition. 
Thyrotoxic periodic paralysis Can present with hypokalaemic periodic paralysis, most commonly seen in Asian males. Essential to check 
TFTs in all first presentations of hypoPP as treatment of the thyrotoxicosis abolishes the episodes of periodic 
paralysis. 
Migraine (hemiplegic migraine) Usually there is a headache history to guide diagnosis but non-headache symptoms may predominate. 
Paroxysmal movement disorders e.g. PKD, 
GLUT1 deficiency, episodic ataxia 
Patients may use the term “weakness” erroneously when it is difficult to quantify a symptom 
Functional disorder Most commonly a functional episodic weakness confused with periodic paralysis 
 
Table 2: differential diagnoses of skeletal muscle channelopathies
Figure Legends 
Figure 1: the skeletal muscle channelopathies – causative genes, dysfunctional ion channel 
and resultant clinical symptom 
Figure 2: discerning features in hypokalaemic and hyperkalaemic periodic paralysis 
Figure 3: MRI STIR images of both calves in a patient with myotonia congenita 
demonstrating the “central stripe” in both left and right medial gastrocnemius muscles 
(arrowheads). Fig reproduced26 
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